07.07.2020

Kaneka Eurogentec receives GMP accreditation for its new state-of-the-art facility in time for the production of DNA vaccines against COVID-19

Kaneka Eurogentec, a custom service and FDA inspected Contract Development and Manufacturing Organization (CDMO) is proud to announce the certification of its new GMP Facility by the Belgian Federal Agency for Medicines and Health Products, FAMHP.

The new state-of-the-art facility allows the large-scale production of new generation of medicines.

State-of-the-art Facilities

The new facility audited and certified by Belgian Authorities is equipped with a 2200 L fermenter and is ready to start operating from this summer. It will complement the current biopharmaceuticals production capacity to further expand the offer from clinical studies (Phases I, II, III) to commercialisation.

Large batch production of therapeutic molecules

Our multi-product facility is located on a single site and allows the development and the production of large scale of current and new generation of drugs and vaccines.

Beside the production of complex GMP recombinant proteins, conjugates and antibody fragments, Kaneka Eurogentec is considered as the world leader in Kg-scale biomanufacturing of GMP plasmid DNA for gene and cell therapies.

It will allow to respond to the need of pharma and biotech customers by producing in microorganisms large batches of plasmid DNA (corresponding to millions of doses) according to the GMP requirements, to be used as DNA vaccines or as starting material for mRNA and viral vectors.

Key Actor in Gene therapy

GMP plasmid DNA and mRNA are considered as a new generation of therapeutics for various medical indications such as cancer vaccines, allergies, cardiovascular or metabolic disorder.

Accordingly, we are already in discussion with Pharma and large Biotech companies for the development and production of DNA based vaccines for testing trials for COVID-19 treatment.

More than 80 new employees

We already hired more than 80 full time scientific staff trained in the production of GMP therapeutic production and 50 are still upcoming for the whole company.

EU Biotech Campus: construction works have begun to build and develop the biotech sector and talents of the future in Wallonia

This state-of-the-art training centre with business accelerator – supported by essenscia – has an ambitious mission. Train more talent and support more start-ups and scale-ups to further strengthen the leading international position of the Belgian and Walloon biotech and biopharmaceutical sector.

Xpress Biologics moves up a gear with Polyplus & SSB

Belgian CDMO Xpress Biologics becomes a strategic enabler of gene therapy production for Polyplus (now to be acquired by Sartorius Stedim Biotech).

Takeda Invests Close to 300 Million Euros in its Plasma-Derived Therapies Production Site in Lessines

The investment encompasses a new production facility and a carbon net-zero emissions warehouse.

Interested in updates on our insights, news and testimonials?